First Brain-Crossing Hunter Syndrome Drug Wins FDA Approval

After 20 years without new treatments, the FDA approved Avlayah, the first therapy designed to treat both physical and neurological symptoms of Hunter syndrome.

The breakthrough offers hope to families battling this rare disease that causes progressive organ damage and early death.